GlassScriptPhysician profile
Cedric Sonny Pratt
NPI 1235345414
$10,839.00
in general payments reported to CMS, 2019-2025
24 companies · $888 in 2025
The $888 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $394 · 2021: $268 · 2022: $610 · 2023: $5,076 · 2024: $3,148 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,825 · Food and Beverage: $2,584 · Travel and Lodging: $502 · Entertainment: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,825.00 |
| Food and Beverage | $2,584.28 |
| Travel and Lodging | $502.00 |
| Entertainment | $200.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,719.52 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $899.31 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $645.23 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $636.10 | 2020-2025 | |
| Astellas Pharma US INC | $262.13 | 2023-2025 | Izervay |
| Allergan, INC. | $246.04 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $231.59 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $231.57 | 2021-2023 | |
| Optos, INC. | $200.53 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $120.12 | 2019-2020 | |
| Alcon Vision LLC | $110.41 | 2019 | |
| Ani Pharmaceuticals, INC. | $101.45 | 2025 | Iluvien, Yutiq, Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $95.27 | 2023 | Xipere, Visudyne |
| Genentech, INC. | $79.60 | 2024 | Susvimo, Vabysmo |
| Harrow Eye, LLC | $43.25 | 2023-2024 | Iheezo, Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $40.80 | 2024 | Hylenex Recombinant |
| Biogen, INC. | $40.58 | 2022 | |
| Astellas Pharma Global Development | $25.58 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $23.78 | 2021 | |
| Biotissue Holdings INC. | $21.40 | 2020 | |
| Vyera Pharmaceuticals, LLC | $19.05 | 2020 | |
| Spark Therapeutics, INC. | $18.02 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.71 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedric Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.